U.S. Markets open in 7 hrs 52 mins

Bristol-Myers Squibb: Losing Otezla Might Be Challenging

Margaret Patrick
Bristol-Myers Squibb: Losing Otezla Might Be Challenging

In the latest update on the pending merger with Celgene (CELG), Bristol-Myers Squibb (BMY) proposed plans to divest Otezla—Celgene’s top-selling non-biologic psoriasis drug.